Navigation Links
Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
Date:1/10/2012

ROCKVILLE, Md., Jan. 10, 2012 /PRNewswire/ -- Biologics drug development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that its customer Sumagen, Co., Ltd., (Seoul, S. Korea and London, ON) will begin clinical trials of their revolutionary HIV vaccine design. The Food and Drug Administration approved Phase I clinical trial will begin in January.

The design and testing of the vaccine was spearheaded by Dr. Chil-Yong Kang, a professor at University of Western Ontario's (UWO) medical school. Dr. Dale VanderPutten of Omnia Biologics commented on the development, "To date experimental HIV vaccines have been largely either subunit vaccines or used non-HIV vaccine vectors and have universally failed in the clinic.  Dr. Kang and his team took a page from the successes of polio, flu, rabies and other highly effective vaccines focusing instead on a viral vaccine that is genetically attenuated, irradiated and chemically inactivated."

Omnia participated in the international effort to propel this important advance into the clinic by providing process and assay development services and manufacturing the vaccine under GMP for South Korean biotech company Sumagen Co. Ltd and their academic partner Dr. Kang and UWO.  Preclinical testing has shown the vaccine to be safe and produce strong immune responses.

Steve Hubert, Vice-President of Operations at Omnia commented on his team's success, "It is especially heartening for our team at Omnia to be able to translate this important technology into the clinic as other well established contract manufacturers failed in their attempts to produce the vaccine at clinical scale."

About Omnia Biologics:  (www.omniabiologics.com)

Omnia offers translational medicine services in the areas of process development, assay development, GMP manufacture, and fill-finish for preclinical and clinical programs for novel therapeutics platforms.  These include vaccines, autologous therapeutics, new gene therapy platforms, and stem cell technologies.  The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world.


'/>"/>
SOURCE Omnia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
2. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
3. Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy
4. Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
6. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
7. Spring Creek Healthcare Systems Initiates Strategy to Partner and License DelRX Patents
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
9. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
10. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
11. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental ... ... markets for Dental Implants in US$ Million. The report provides separate comprehensive ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through ...
(Date:3/24/2017)... 2017 ShangPharma, a leading life ... drug development and discovery services, technology, and ... announced today the intent for a strategic ... consolidating the Contract Research Organizations (CRO) and ... These entities include ChemPartner Shanghai, ChemPartner Fengxian, ...
(Date:3/24/2017)... FinancialBuzz.com News Commentary   ... Medical cannabis products around the world are projected to ... global medical cannabis market will reach a value of USD 55.8 billion ... for the new growing industry. By the end of 2016, 28 states ... medical cannabis. More conservative states like Arkansas and ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
(Date:3/24/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) has named ... in their 12th year, are among the most prestigious in radiology marketing because a ... were retooled to recognize achievements in both large budget (over $5,000) and small budget ...
(Date:3/24/2017)... San Antonio, TX (PRWEB) , ... March 24, 2017 , ... ... a new clinic which can be found at 9618 Huebner Road. The clinic is ... Thobaben, PT, OCS, Clinic Director, and Dr. Ali Higgins, PT, will provide care from ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... financial planning, and related services to families and business owners across eastern Michigan, ... at feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food ...
(Date:3/24/2017)... ... March 24, 2017 , ... In just ... EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone ... with nearly 2,000 consumers (and counting) already backing the campaign. , “We ...
Breaking Medicine News(10 mins):